Former Fogarty trainees help eliminate hepatitis C in Georgia

September / October 2015 | Volume 14, Issue 5

Full September / October 2015 Global Health Matters newsletter [PDF <1M]

A female researcher wearing gloves works with samples in a lab in Georgia

Photo by Zaza Macharashvili

Fogarty has supported efforts to build research capacity in
Georgia for two decades and scientists there are working on
eliminating hepatitis C from their country.

By Cathy Kristiansen

Georgia has launched a groundbreaking program to rid its population of hepatitis C - the first lower-middle-income country to tackle this challenge since a cure was discovered for the devastating disease. Leading the effort are a number of former Fogarty trainees, who are collaborating with the U.S. CDC and a pharmaceutical company that is donating its new drug.

As many as 150 million people globally are infected with the hepatitis C virus (HCV), resulting in about 500,000 deaths annually from cirrhosis or cancer of the liver, according to the WHO. Georgia reports one of the world's highest estimated HCV prevalence rates, reaching as much as 80 percent among its HIV-positive population, injection drug users and prisoners. The scientific team believes the country is an ideal candidate for HCV elimination with its small size and high prevalence of disease; strong governmental commitment; availability of modern diagnostic and treatment methods; and a cadre of well-trained personnel who are capable of planning and implementing such a complex initiative.

"It's a strikingly innovative program," said longtime Fogarty grantee, Dr. Jack A. DeHovitz, of SUNY Downstate Medical Center, who has trained Georgian scientists with Fogarty funding since 1996. "It's fair to say that without the Fogarty investment, this would not be happening."

Georgia's research strength to tackle this disease, HIV and other health burdens is founded on the steady build-up of capacity over the past two decades. Key support came from Fogarty's training programs and research projects orchestrated by four grantees - DeHovitz, Drs. Carlos del Rio and Henry M. Blumberg of Emory University, and Dr. Dale L. Morse, now at the CDC.

The group has together trained about 100 Georgian scientists, which was critical to developing the human resources required to eliminate HCV, del Rio noted. "Fogarty was the gel that allowed us to collaborate and help build a strong public health sector when it wasn't really in vogue." Georgia's research infrastructure had been devastated by a civil war that ended in 1993 and the first Fogarty support came only a few years later.

In 2014, a new medicine became available that, in combination with other drugs, cures nearly all HCV patients in 12 weeks. Georgian scientists saw this as an opportunity to eliminate the virus in their country. They partnered with the U.S. CDC to prepare the groundwork, such as conducting epidemiological studies, priming laboratory and health care capacity, and setting up an evaluation framework. Gilead Sciences, Inc. offered free supplies of its drugs Sovaldi and Harvoni, which would normally cost about $84,000 per patient.

"The knowledge and skills we gained during Fogarty-funded training are a very important contribution to the preparation of this intervention," said Dr. Maia Butsashvili, a hepatitis C project scientist, who obtained her doctoral degree in epidemiology with Fogarty support.

So far, the team has selected seven clinical sites and associated labs to pilot the program. They also developed a data management system to track patients and collect demographic, diagnostic, clinical and pharmacy information. By September, more than 10,000 patients with HCV had registered and about 3,000 had begun treatment.

Georgia faces many challenges in reaching the point of hepatitis C elimination, mainly due to the difficulty in identifying the virus before it causes symptoms and its rapid spread through injection drug use, noted the authors of a CDC report on the project. However, the government is addressing these through advocacy, communication, surveillance and prevention strategies, they added.

One of Georgia's first Fogarty trainees, Dr. Tengiz Tsertsvadze, is helping to guide the HCV effort. Tsertsvadze, now director of the infectious disease research center in Tbilisi and professor of medicine at Tbilisi State University, hopes his country's example will be a guide to others battling HCV. "Through best practices and lessons learned," he said, "the international community can follow Georgia's successful experience to significantly reduce the devastating burden of hepatitis C."

More Information

Related resources:

Learn more about Fogarty-supported research and training in Georgia.
About NIH Hepatitis research from the National Institute of Allergy and Infectious Diseases (NIAID).
Launch of a Nationawide Hepatitis C Elimination Program-Georgia
CDC Morbidity and Mortality Weekly Report, April 2015
World Health Organization (WHO) resources:

Top NIH Funding News

Important news from NIH for all grantees.

Significant Changes: FY 2016 NIH Grants Policy Statement (NOT-OD-16-017)

Funding Opportunities

NIH funding opportunities focusing on global health and foreign collaboration.

International Centers of Excellence for Malaria Research (U19) (RFA-AI-15-056)
Application Receipt Date(s): April 15, 2016
More about NIAID's International Centers of Excellence for Malaria Research (ICEMR).

NIH funding opportunities for which foreign organizations, foreign components of U.S. organizations and/or other foreign components may apply.

HIV/AIDS High Priority Drug Abuse Research (R01) (PAS-16-018)
Application Receipt/Submission Date(s): Multiple dates, see announcement.
Metabolomics Data Analysis (R03) (RFA-RM-15-021)
Application Receipt Date(s): February 11, 2016
Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases(U01) (PAR-16-020)
Application Receipt/Submission Date(s): February 18, 2016; August 18, 2016; February 17, 2017; and more
NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders(X01) (PAR-16-021)
Application Receipt/Submission Date(s): January 19, 2016; January 19, 2017; January 19, 2018; and more
Human Pancreas Procurement and Analysis Program (HPPAP) (UC4) (RFA-DK-15-027)
Application Receipt Date(s): March 03, 2016
Outstanding New Environmental Scientist (ONES) Award (R01) (RFA-ES-15-020)
Application Receipt Date(s): February 26, 2016; February 28, 2017; February 27, 2018
Innovative Questions in Symptom Science and Genomics (R15) (PA-16-022),(R21) (PA-16-023) and (R01) (PA-16-024)
Application Receipt/Submission Date(s): Multiple dates, see announcement.
Novel Genomic Technology Development (R01) (PAR-16-014), (R21) (PAR-16-015) and (R43/R44) (PAR-16-016)
Application Receipt/Submission Date(s): January 14, 2016; October 31, 2016; October 31, 2017
Novel Nucleic Acid Sequencing Technology Development - Direct to Phase II(R44) (RFA-HG-15-039)
Application Receipt Date(s): August 07, 2016

Events

Information about NIH events for global health researchers.

National Institute on Drug Abuse (NIDA) International Forum
June 10 - 13, 2016
Palm Springs, CA
Submit abstracts and apply for travel awards by January 4, 2016.

Funding News

NIH funding news that may be relevant to global health researchers.

Soliciting Input for the Office of Behavioral and Social Sciences Research (OBSSR) FY 2016-2020 Strategic Plan (NOT-OD-16-018)
Request for Information: Randomized Controlled Trials (RCTs) of Lifestyle Weight Loss Interventions for Genome Wide Association Studies (NOT-CA-15-042)
Extension of Expiration Dates for AHRQ Fellowship (F) and Career Development Award (K) Funding Opportunity Announcements (PA-12-261 and PA-13-039) (NOT-HS-16-001)
NHLBI Announces Interest in:

Administrative Supplements to Enhance HIV-related Heart, Lung, Blood, and Sleep Research (NOT-HL-15-279)
R01 Studies Addressing the Epidemiology of HIV-Related Heart, Lung, and Blood Diseases and Sleep Disorders for PAR-15-280 Multidisciplinary Studies of HIV/AIDS and Aging (R01) (NOT-HL-15-278)
Omics-Related R01 Applications for RFA-HL-14-024 Basic Research in the Pathogenesis of HIV-Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01) (NOT-HL-15-280)
Epidemiology-Related R01 Applications for RFA-HL-14-023 Clinical Research in the Prevention, Diagnosis, and Treatment of HIV-Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01) (NOT-HL-15-281)